Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. on December 20, 2017, regarding an event that occurred on December 18, 2017. The filing addresses a change in the composition of the Board of Directors related to the Series A 4.5% Convertible Preferred Stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Appointment: Xi Chen, Ph.D., has been appointed to replace Zhang Zhuo as the director appointee for the Company's Series A Stock.
- Shareholder Authority: The appointment was made by Tianjin Pharmaceuticals Group International Holdings Co., LTD, the sole shareholder of the Series A Stock.
- Term: Dr. Chen will serve as a Class III director until the 2020 annual shareholder meeting or until resignation/removal.
- Compensation: Dr. Chen will participate in the existing non-executive board compensation policy.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No new risks or contingencies were disclosed in this report. The document notes there are no family relationships between Dr. Chen and existing executive officers or directors.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.01 for additional context on the appointment.
- Review the June 27, 2017 Form 8-K to understand the specific terms of the non-executive board compensation policy applicable to Dr. Chen.
- Confirm the voting rights and conversion terms of the Series A 4.5% Convertible Preferred Stock held by Tianjin Pharmaceuticals Group.